Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMV-12 + Osimertinib in EGFR-mutant NSCLC
NCT06109558Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of LMV-12 in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Hunan Cancer Hospital. Primary endpoints: Objective Response Rate up to 36 months, Adverse Events and Safety up to 36 months and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
LMV-12
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06109558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109558.